Back To: Home : Featured Technology : Microbiome

CLICK HERE FOR WHAT'S NEW IN:
 

Momenta secures Virdante assets for $4.5 million
January 2012
SHARING OPTIONS:

CAMBRIDGE, Mass.—Biotechnology company Momenta Pharmaceuticals Inc., which specializes in detailed structural analysis of complex mixture drugs, has announced the acquisition of Virdante Pharmaceuticals Inc.'s Sialic Switch assets for $4.5 million upfront, with an additional $51.5 million in milestone payments possible if all development and regulatory milestones are met. The acquisition includes intellectual property and cell lines relating to the sialylation of intravenous immunoglobulin and other proteins. Virdante's Sialic Switch technology is centered on activating a novel anti-inflammatory pathway by sialylating Fc-linked glycans of IgG antibodies.  
 
Dr. Ganesh Venkataraman, chief scientific officer of Momenta, said in a press release, "Sialylation complements our existing technology platform, and we look forward to advancing this technology in development programs, including biobetters and novel products."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.